Achieving Nutritional Adequacy Of Vitamin E With An Egg/Plant-Based Food Pairing
1 other identifier
interventional
8
1 country
1
Brief Summary
Malnutrition of the fat-soluble nutrient vitamin E (α-tocopherol; αT) is problematic. Since αT is rich in plant foods (e.g. spinach) that are mostly absent of accessible lipid, dietary patterns that can potentiate αT bioavailability by pairing vegetables with lipid-rich foods have been emphasized. The purpose of this study is to use deuterium-labeled spinach (containing stable isotopes of αT) to validate eggs as a dietary tool to improve αT bioavailability directly from a model plant food, and hence achieve nutrient adequacy. It is expected that compared with deuterium-labeled spinach alone, co-ingestion of eggs will dose- and time-dependently increase plasma bioavailability of spinach-derived deuterium-labeled αT without affecting time to maximal concentrations or half-lives. Further, phospholipid-rich egg yolk lipid will enhance nutrient bioavailability compared with vegetable oil. The outcome will therefore support an egg-based food pairing that can enhance the health benefits of plant-centric dietary patterns.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 22, 2020
CompletedFirst Posted
Study publicly available on registry
February 27, 2020
CompletedStudy Start
First participant enrolled
June 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 15, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 15, 2024
CompletedResults Posted
Study results publicly available
December 2, 2025
CompletedDecember 2, 2025
November 1, 2025
3.1 years
February 22, 2020
August 14, 2025
November 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Vitamin E Area Under the Curve (0-72 h)
Area under the concentration-time curve of plasma deuterium-labeled alpha-tocopherol over 72 hours post ingestion.
0, 3, 4.5, 6, 7.5, 9, 12, 24, 36, 48, 72 hours post-ingestion of spinach
Vitamin E Cmax
Maximum plasma concentration of deuterium-labeled alpha-tocopherol
0-72 hours post-ingestion of spinach
Secondary Outcomes (4)
Vitamin E Tmax (hr)
0-72 hours post-ingestion of spinach
Half-Life (hr)
0-72 hours post-ingestion of spinach
Estimated Absorption (%Dose) of Vitamin E
0-72 hours post-ingestion of spinach
Chylomicron Vitamin E
0, 3, 4.5, 6, 7.5, 9, 12 hours post-ingestion of spinach
Study Arms (8)
Zero hard-boiled egg at 0 h
EXPERIMENTALNo eggs will be consumed on the test day. Deuterium-labeled spinach containing 5 mg αT will be ingested alone prior to the 72-h pharmacokinetics trial.
One hard-boiled egg at 0 h
EXPERIMENTALDeuterium-labeled spinach containing 5 mg αT will be ingested along with 1 hard-boiled egg prior to the 72-h pharmacokinetics trial.
Two hard-boiled eggs at 0 h
EXPERIMENTALDeuterium-labeled spinach containing 5mg αT will be ingested along with 2 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
Three hard-boiled eggs at 0 h
EXPERIMENTALDeuterium-labeled spinach containing 5 mg αT will be ingested along with 3 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
One hard-boiled egg at 3 h
EXPERIMENTALDeuterium-labeled spinach containing 5 mg αT will be ingested alone at 0 h prior to the 72-h pharmacokinetics trial followed by 1 hard-boiled egg 3 hours after spinach consumption.
One hard-boiled egg at 0 h + One hard-boiled egg at 3 h
EXPERIMENTALDeuterium-labeled spinach containing 5 mg αT will be ingested along with 1 hard-boiled egg at 0 h prior to the 72-h pharmacokinetics trial followed by 1 egg 3 hours after spinach consumption.
Two egg whites at 0 h
EXPERIMENTALDeuterium-labeled spinach containing 5 mg αT will be ingested along with two egg whites prior to the 72-h pharmacokinetics trial.
Vegetable oil at 0 h
EXPERIMENTALDeuterium-labeled spinach containing 5 mg αT will be ingested along with 9.6 grams of vegetable oil prior to the 72-h pharmacokinetics trial.
Interventions
No eggs will be consumed on test day along with spinach consumption
One egg will be consumed on test day along with spinach consumption
Two eggs will be consumed on test day along with spinach consumption
Three eggs will be consumed on test day along with spinach consumption
One egg will be consumed on test day three hours after spinach consumption
Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption
Two egg whites will be consumed on test day along with spinach consumption
9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption
Eligibility Criteria
You may qualify if:
- Body Mass Index (BMI) = 19-25 kg/m2
- Normolipidemic (total cholesterol \<240 mg/dL; triglyceride \<150 mg/dL)
- Fasting glucose \<100 mg/dL
- Normal hematocrit level (41%-50% for men and 36%-48% for women)
- Normal hemoglobin level (13.5-17.5 g/dL for men and 12.0-15.5 g/dL for women)
- No use of dietary supplements for \>1 month
- No use of medications that affect lipid or glucose metabolism
- Non-smoker
- No history of gastrointestinal disorders
You may not qualify if:
- Egg allergy
- Alcohol intake \> 2 drinks per day
- Aerobic activity \>7 h/wk
- Body mass change \>2 kg in the past 1 month
- Women who are pregnant, lactating, or initiated or changed birth control in the past 3 month
- Vegetarian
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ohio State University
Columbus, Ohio, 43210, United States
Results Point of Contact
- Title
- Dr. Richard Bruno
- Organization
- Ohio State University
Study Officials
- PRINCIPAL INVESTIGATOR
Richard S Bruno, Ph.D.
Ohio State University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor and Principal Investigator
Study Record Dates
First Submitted
February 22, 2020
First Posted
February 27, 2020
Study Start
June 1, 2021
Primary Completion
July 15, 2024
Study Completion
July 15, 2024
Last Updated
December 2, 2025
Results First Posted
December 2, 2025
Record last verified: 2025-11